| 129.64 3.68 (2.92%) | 11-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 152.38 |
1-year : | 177.99 |
| Resists | First : | 130.47 |
Second : | 152.38 |
| Pivot price | 122.21 |
|||
| Supports | First : | 107.93 |
Second : | 94 |
| MAs | MA(5) : | 123.76 |
MA(20) : | 119.38 |
| MA(100) : | 102.92 |
MA(250) : | 102.35  |
|
| MACD | MACD : | 5.7 |
Signal : | 5.5 |
| %K %D | K(14,3) : | 82.8 |
D(3) : | 75.8 |
| RSI | RSI(14): 70.7 |
|||
| 52-week | High : | 153.05 | Low : | 68.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ILMN ] has closed above the upper band by 22.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 130.67 - 131.19 | 131.19 - 131.74 |
| Low: | 124.23 - 124.77 | 124.77 - 125.32 |
| Close: | 128.74 - 129.69 | 129.69 - 130.67 |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Sun, 23 Nov 2025
Illumina, Inc. Stock (ILMN) Opinions on Strategic Growth and Market Expansion - Quiver Quantitative
Tue, 11 Nov 2025
Illumina To Webcast Upcoming Investor Conference - PR Newswire
Sun, 09 Nov 2025
Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected - simplywall.st
Fri, 07 Nov 2025
Illumina: An Excellent Profit Margin And The Sequencing Genome Market Will Unlock Value - Seeking Alpha
Wed, 05 Nov 2025
Illumina Responds to Positive Updates from Chinese Ministry of Commerce - PR Newswire
Sun, 02 Nov 2025
Illumina (ILMN) Soars 23.4% on Earnings Beat - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 153 (M) |
| Shares Float | 148 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 105.1 (%) |
| Shares Short | 6,730 (K) |
| Shares Short P.Month | 6,610 (K) |
| EPS | 4.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.56 |
| Profit Margin | 16.3 % |
| Operating Margin | 21.3 % |
| Return on Assets (ttm) | 9.1 % |
| Return on Equity (ttm) | 31.2 % |
| Qtrly Rev. Growth | 0.4 % |
| Gross Profit (p.s.) | 19.17 |
| Sales Per Share | 28.07 |
| EBITDA (p.s.) | 7.65 |
| Qtrly Earnings Growth | -77.9 % |
| Operating Cash Flow | 1,120 (M) |
| Levered Free Cash Flow | 840 (M) |
| PE Ratio | 29.06 |
| PEG Ratio | 0 |
| Price to Book value | 8.33 |
| Price to Sales | 4.61 |
| Price to Cash Flow | 17.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|